Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep 1;130(5):414-437.
doi: 10.1352/1944-7558-130.5.414.

Characterizing Developmental and Behavioral Profiles in Developmental Synaptopathies to Inform Clinical Trial Endpoints

Latha Valluripalli Soorya  1 , Camille W Brune  1 , Cristan A Farmer  1 , Edith V Ocampo  1 , Natalie I Berger  1 , Deborah A Pearson  1 , Robyn M Busch  1 , Patricia Klaas  1 , Paige Siper  1 , Kristn Currans  1 , Amanda C Gulsrud  1 , Jennifer M Phillips  1 , Rajna Filip-Dhima  1 , Sarah E O'Kelley  1 , Thomas W Frazier  1 , Tess Levy  1 , Allison L Wainer  1 , Joseph D Buxbaum  1 , Craig M Powell  1 , Jonathan A Bernstein  1 , Simon K Warfield  1 , Darcy A Krueger  1 , E Martina Bebin  1 , Hope Northrup  1 , Shafali S Jeste  1 , Alexander Kolevzon  1 , Elizabeth Berry-Kravis  1 , Mustafa Sahin  1 , Siddharth Srivastava  1 , Audrey Thurm  1 ; Developmental Synaptopathies Consortium
Affiliations

Characterizing Developmental and Behavioral Profiles in Developmental Synaptopathies to Inform Clinical Trial Endpoints

Latha Valluripalli Soorya et al. Am J Intellect Dev Disabil. .

Abstract

The Developmental Synaptopathies Consortium is a multisite natural history network studying rare, neurogenetic syndromes associated with synaptic dysfunction and developmental delays. One aim of the Consortium is clinical trial readiness, including identifying clinical concepts and validating their measurement. We evaluated the scope and limitations of conventional cognitive and behavioral measurement strategies in 2-21-year-olds with Phelan-McDermid syndrome (PMS; N = 98), Tuberous Sclerosis Complex (TSC; N = 98), and PTEN Hamartoma Tumor syndrome (PHTS; N = 69). On average, intellectual disability (ID) severity was severe-to-profound in PMS, mild-to-moderate for TSC, and borderline (or absent) in PHTS. Severity of ID invalidated the use of many assessments, including standardized autism diagnostic measures. These results will inform trial planning for these and other similarly medically complex neurodevelopmental conditions.

Keywords: PTEN Hamartoma Tumor syndrome; Phelan McDermid syndrome; autism spectrum disorder; clinical trial readiness; intellectual disability; neurodevelopmental disorders; neuropsychological assessment; tuberous sclerosis complex.

PubMed Disclaimer

Supplementary concepts